Search

Your search keyword '"Al Bakir, M"' showing total 75 results

Search Constraints

Start Over You searched for: Author "Al Bakir, M" Remove constraint Author: "Al Bakir, M"
75 results on '"Al Bakir, M"'

Search Results

1. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

2. Genomic–transcriptomic evolution in lung cancer and metastasis

3. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

4. The evolution of lung cancer and impact of subclonal selection in TRACERx

5. Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

7. The evolution of lung cancer and impact of subclonal selection in TRACERx

10. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

11. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

12. 889P Development of a head and neck immune prognostic index (HN-IPI) classification for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs)

13. Using DNA sequencing data to quantify T cell fraction and therapy response

15. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

16. The T cell differentiation landscape is shaped by tumour mutations in lung cancer

17. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

18. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma

21. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

22. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution

23. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

24. An Audit of the Use of Cabazitaxel for the Treatment of Metastatic Castrate Resistant Prostate Cancer (mCRPC) Compared with Previous Experience with ECarboF (Epirubicin, Carboplatin and 5-fluorouracil) in a Single Institution

27. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

28. Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

29. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

30. Single-centre experience of implementing physiotherapist-led prehabilitation for chimeric antigen receptor T cell therapy.

31. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.

32. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.

33. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models.

34. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.

35. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.

36. Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.

37. The evolution of non-small cell lung cancer metastases in TRACERx.

38. The evolution of lung cancer and impact of subclonal selection in TRACERx.

39. Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

40. Genomic-transcriptomic evolution in lung cancer and metastasis.

41. Lung adenocarcinoma promotion by air pollutants.

42. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer.

43. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.

44. Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.

45. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.

46. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.

47. Publisher Correction: A clonal expression biomarker associates with lung cancer mortality.

48. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.

49. Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.

50. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.

Catalog

Books, media, physical & digital resources